|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IFT81 |
Gene summary for IFT81 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IFT81 | Gene ID | 28981 |
| Gene name | intraflagellar transport 81 | |
| Gene Alias | CDV-1 | |
| Cytomap | 12q24.11 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024RBJ1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 28981 | IFT81 | LZE7T | Human | Esophagus | ESCC | 8.85e-03 | 1.97e-01 | 0.0667 |
| 28981 | IFT81 | LZE24T | Human | Esophagus | ESCC | 4.03e-05 | 2.23e-01 | 0.0596 |
| 28981 | IFT81 | P1T-E | Human | Esophagus | ESCC | 4.78e-06 | 2.97e-01 | 0.0875 |
| 28981 | IFT81 | P2T-E | Human | Esophagus | ESCC | 1.46e-44 | 7.73e-01 | 0.1177 |
| 28981 | IFT81 | P4T-E | Human | Esophagus | ESCC | 4.89e-21 | 4.81e-01 | 0.1323 |
| 28981 | IFT81 | P5T-E | Human | Esophagus | ESCC | 4.32e-04 | 1.11e-01 | 0.1327 |
| 28981 | IFT81 | P8T-E | Human | Esophagus | ESCC | 4.30e-21 | 4.09e-01 | 0.0889 |
| 28981 | IFT81 | P9T-E | Human | Esophagus | ESCC | 8.04e-06 | 1.73e-01 | 0.1131 |
| 28981 | IFT81 | P10T-E | Human | Esophagus | ESCC | 2.02e-16 | 3.47e-01 | 0.116 |
| 28981 | IFT81 | P11T-E | Human | Esophagus | ESCC | 2.12e-03 | 2.50e-01 | 0.1426 |
| 28981 | IFT81 | P12T-E | Human | Esophagus | ESCC | 9.86e-10 | 1.66e-01 | 0.1122 |
| 28981 | IFT81 | P15T-E | Human | Esophagus | ESCC | 1.74e-04 | 1.59e-01 | 0.1149 |
| 28981 | IFT81 | P16T-E | Human | Esophagus | ESCC | 5.11e-33 | 5.71e-01 | 0.1153 |
| 28981 | IFT81 | P17T-E | Human | Esophagus | ESCC | 3.35e-03 | 1.90e-01 | 0.1278 |
| 28981 | IFT81 | P19T-E | Human | Esophagus | ESCC | 2.80e-04 | 3.29e-01 | 0.1662 |
| 28981 | IFT81 | P20T-E | Human | Esophagus | ESCC | 1.47e-09 | 1.98e-01 | 0.1124 |
| 28981 | IFT81 | P21T-E | Human | Esophagus | ESCC | 1.88e-19 | 4.05e-01 | 0.1617 |
| 28981 | IFT81 | P22T-E | Human | Esophagus | ESCC | 6.60e-14 | 2.49e-01 | 0.1236 |
| 28981 | IFT81 | P23T-E | Human | Esophagus | ESCC | 2.87e-04 | 1.98e-01 | 0.108 |
| 28981 | IFT81 | P24T-E | Human | Esophagus | ESCC | 1.02e-06 | 1.60e-01 | 0.1287 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003070518 | Esophagus | ESCC | cytoskeleton-dependent intracellular transport | 133/8552 | 195/18723 | 1.48e-10 | 4.27e-09 | 133 |
| GO:001097013 | Esophagus | ESCC | transport along microtubule | 107/8552 | 155/18723 | 3.17e-09 | 6.80e-08 | 107 |
| GO:003150314 | Esophagus | ESCC | protein-containing complex localization | 139/8552 | 220/18723 | 1.14e-07 | 1.85e-06 | 139 |
| GO:00991114 | Esophagus | ESCC | microtubule-based transport | 115/8552 | 190/18723 | 2.54e-05 | 2.15e-04 | 115 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IFT81 | SNV | Missense_Mutation | rs113298674 | c.296A>G | p.Tyr99Cys | p.Y99C | Q8WYA0 | protein_coding | deleterious(0.01) | possibly_damaging(0.757) | TCGA-A7-A4SA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| IFT81 | SNV | Missense_Mutation | c.491N>G | p.Ser164Cys | p.S164C | Q8WYA0 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| IFT81 | SNV | Missense_Mutation | c.1783N>C | p.Glu595Gln | p.E595Q | Q8WYA0 | protein_coding | tolerated(0.06) | benign(0.311) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| IFT81 | SNV | Missense_Mutation | c.379N>A | p.Val127Ile | p.V127I | Q8WYA0 | protein_coding | tolerated(0.37) | benign(0.127) | TCGA-E2-A15G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| IFT81 | SNV | Missense_Mutation | novel | c.1790N>T | p.Arg597Ile | p.R597I | Q8WYA0 | protein_coding | deleterious(0) | benign(0.131) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| IFT81 | SNV | Missense_Mutation | c.1505N>T | p.Ser502Leu | p.S502L | Q8WYA0 | protein_coding | deleterious(0.01) | benign(0.311) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| IFT81 | SNV | Missense_Mutation | c.1429N>A | p.Glu477Lys | p.E477K | Q8WYA0 | protein_coding | deleterious(0.01) | possibly_damaging(0.853) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| IFT81 | SNV | Missense_Mutation | novel | c.1050C>G | p.Ile350Met | p.I350M | Q8WYA0 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-VS-A9UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| IFT81 | SNV | Missense_Mutation | rs527626533 | c.1738C>T | p.Arg580Cys | p.R580C | Q8WYA0 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IFT81 | SNV | Missense_Mutation | novel | c.394N>A | p.Leu132Ile | p.L132I | Q8WYA0 | protein_coding | tolerated(0.05) | possibly_damaging(0.828) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |